Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Monomorphic epitheliotropic intestinal T-cell lymphoma, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
There is no randomised evidence of any kind in this disease, and the best comparison available is a retrospective cohort of 50 treated patients.
Whether methotrexate should be included to prevent relapse in the central nervous system is unresolved: the regimen that performed better left it out, and the two-year risk of relapse in the brain or spinal cord was still 12.1 per cent.
Because it is diagnosed on resected bowel after emergency surgery in many cases, the population that reaches systemic treatment is selected, and the published survival figures reflect that.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 6 changes by month →When this page itself was last checked or edited.
There is no randomised evidence of any kind. The largest real-world comparison took 50 patients who received systemic chemotherapy and compared a modified version of the Newcastle regimen developed for enteropathy-associated T-cell lymphoma, giving cyclophosphamide, doxorubicin, vincristine and prednisone alternating with ifosfamide, etoposide and epirubicin but leaving out the methotrexate, against ordinary chemotherapy of the same backbone: median progression-free survival 14.4 against 6.6 months and overall survival 28.7 against 11.7 months, with the regimen remaining an independent predictor of better progression-free survival after adjustment. The two-year cumulative incidence of relapse in the central nervous system was 12.1 per cent, which is what the omitted methotrexate had been intended to prevent. Entry into a trial is a reasonable first choice rather than a last resort.
In 50 patients receiving systemic chemotherapy, a modified Newcastle regimen without methotrexate gave median progression-free survival of 14.4 months against 6.6 and overall survival of 28.7 against 11.7 months compared with CHOP-based chemotherapy; the two-year cumulative incidence of relapse in the central nervous system was 12.1 per cent.
Often made on small bowel resected as an emergency for perforation or obstruction. What separates it from enteropathy-associated T-cell lymphoma is the absence of coeliac disease, the monotonous small to medium cells rather than varied large ones, a CD8-positive and CD56-positive phenotype, and SETD2 mutation with JAK3 and STAT5B rather than JAK1 and STAT3. Neither carries Epstein-Barr virus, which separates both from NK/T-cell lymphoma of the gut.
WHO-HAEM5 retained the entity and set out the features that separate the five T-cell and NK-cell conditions of the gut from each other, including the mutations that differ between this and enteropathy-associated T-cell lymphoma.
The revised fourth edition of the WHO classification separated what had been called type II enteropathy-associated T-cell lymphoma and named it monomorphic epitheliotropic intestinal T-cell lymphoma, because it has no association with coeliac disease and differs in appearance and genetics.